Skip to content
The Policy VaultThe Policy Vault

Afinitor Disperz — CareFirst (Caremark)

progressive and/or symptomatic papillary or follicular thyroid carcinoma not amenable to radioactive iodine therapy

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months